LIGAND PHARMACEUTICALS INC Quarterly Nonoperating Income (Expense) in USD from Q2 2010 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Summary
Ligand Pharmaceuticals Inc quarterly/annual Nonoperating Income (Expense) history and growth rate from Q2 2010 to Q3 2024.
  • Ligand Pharmaceuticals Inc Nonoperating Income (Expense) for the quarter ending September 30, 2024 was -$9.48M, a 37.7% increase year-over-year.
  • Ligand Pharmaceuticals Inc Nonoperating Income (Expense) for the twelve months ending September 30, 2024 was $75.1M, a 0.48% decline year-over-year.
  • Ligand Pharmaceuticals Inc annual Nonoperating Income (Expense) for 2023 was $51.7M, a 56.8% increase from 2022.
  • Ligand Pharmaceuticals Inc annual Nonoperating Income (Expense) for 2022 was $33M.
  • Ligand Pharmaceuticals Inc annual Nonoperating Income (Expense) for 2021 was -$31.6M, a 12.6% increase from 2020.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $75.1M -$9.48M +$5.74M +37.7% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-08
Q2 2024 $69.4M -$46.3M -$51.4M -998% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-07
Q1 2024 $121M $110M +$69.1M +167% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-08
Q4 2023 $51.7M $20.5M -$23.8M -53.8% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-29
Q3 2023 $75.5M -$15.2M -$15.2M -117192% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-08
Q2 2023 $90.7M $5.15M +$5.16M Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-07
Q1 2023 $85.6M $41.3M +$52.6M Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q4 2022 $33M $44.2M +$64M Oct 1, 2022 Dec 31, 2022 10-K 2024-02-29
Q3 2022 -$31.1M $13K +$460K Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 -$31.5M -$1K* +$12.4M Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-09
Q1 2022 -$44M -$11.3M -$12.3M -1175% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-08
Q4 2021 -$31.6M -$19.8M -$12.1M -158% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-29
Q3 2021 -$19.5M -$447K +$14.9M +97.1% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-08
Q2 2021 -$34.4M -$12.4M -$33.5M -159% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-09
Q1 2021 -$956K $1.05M +$35.3M Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-09
Q4 2020 -$36.2M -$7.67M -$9.67M -482% Oct 1, 2020 Dec 31, 2020 10-K 2023-02-28
Q3 2020 -$26.5M -$15.4M -$646K -4.39% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-09
Q2 2020 -$25.9M $21M +$34.9M Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-03
Q1 2020 -$60.8M -$34.2M -$50.4M -312% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q4 2019 -$10.4M $2M +$91.9M Oct 1, 2019 Dec 31, 2019 10-K 2022-02-28
Q3 2019 -$102M -$14.7M -$70.6M -126% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-06
Q2 2019 -$31.8M -$13.9M -$39.3M -155% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-07
Q1 2019 $7.5M $16.2M -$2.1M -11.5% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-08
Q4 2018 $9.6M -$89.9M -$92.3M -3985% Oct 1, 2018 Dec 31, 2018 10-K 2021-02-24
Q3 2018 $102M $55.9M +$60.3M Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-08
Q2 2018 $41.6M $25.4M +$30.1M Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-08
Q1 2018 $11.4M $18.3M +$22.3M Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-09
Q4 2017 -$10.8M $2.32M +$14.4M Oct 1, 2017 Dec 31, 2017 10-K 2020-02-27
Q3 2017 -$25.3M -$4.42M -$167K -3.93% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-08
Q2 2017 -$25.1M -$4.72M +$9.31M +66.4% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-08
Q1 2017 -$34.4M -$4.02M +$1.5M +27.2% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-09
Q4 2016 -$35.9M -$12.1M -$6.93M -134% Oct 1, 2016 Dec 31, 2016 10-K 2019-02-28
Q3 2016 -$29M -$4.26M -$2.94M -224% Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-09
Q2 2016 -$26M -$14M -$31.9M -178% Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-09
Q1 2016 $5.9M -$5.53M -$2.1M -61.4% Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-09
Q4 2015 $8M -$5.19M -$2.57M -97.7% Oct 1, 2015 Dec 31, 2015 10-K 2018-03-01
Q3 2015 $10.6M -$1.31M +$1.32M +50.1% Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-15
Q2 2015 $9.25M $17.9M +$18M Apr 1, 2015 Jun 30, 2015 10-Q/A 2016-11-15
Q1 2015 -$8.8M -$3.42M -$473K -16% Jan 1, 2015 Mar 31, 2015 10-Q/A 2016-11-15
Q4 2014 -$8.32M -$2.63M +$1.79M +40.6% Oct 1, 2014 Dec 31, 2014 10-K 2017-02-28
Q3 2014 -$10.1M -$2.63M -$1.59M -152% Jul 1, 2014 Sep 30, 2014 10-Q 2015-11-09
Q2 2014 -$8.53M -$117K -$2.41M -105% Apr 1, 2014 Jun 30, 2014 10-Q 2015-08-05
Q1 2014 -$6.13M -$2.95M -$388K -15.1% Jan 1, 2014 Mar 31, 2014 10-Q 2015-05-11
Q4 2013 -$5.74M -$4.42M -$1.1M -33.1% Oct 1, 2013 Dec 31, 2013 10-K/A 2016-11-15
Q3 2013 -$4.64M -$1.05M -$2.42M -176% Jul 1, 2013 Sep 30, 2013 10-Q 2014-10-31
Q2 2013 -$2.22M $2.29M +$4.47M Apr 1, 2013 Jun 30, 2013 10-Q 2014-08-05
Q1 2013 -$6.69M -$2.56M -$2.63M -3982% Jan 1, 2013 Mar 31, 2013 10-Q 2014-05-07
Q4 2012 -$4.06M -$3.32M -$3.65M -1125% Oct 1, 2012 Dec 31, 2012 10-K 2015-02-23
Q3 2012 -$412K $1.37M +$2.28M Jul 1, 2012 Sep 30, 2012 10-Q 2013-11-08
Q2 2012 -$2.69M -$2.18M -$2.7M -511% Apr 1, 2012 Jun 30, 2012 10-Q 2013-08-01
Q1 2012 $12K $66K +$2.69M Jan 1, 2012 Mar 31, 2012 10-Q 2013-05-08
Q4 2011 -$2.68M $324K Oct 1, 2011 Dec 31, 2011 10-K/A 2014-12-12
Q3 2011 -$907K -$5.15M -121% Jul 1, 2011 Sep 30, 2011 10-Q 2012-11-14
Q2 2011 $529K -$3.43M -86.7% Apr 1, 2011 Jun 30, 2011 10-Q/A 2012-11-14
Q1 2011 -$2.63M Jan 1, 2011 Mar 31, 2011 10-Q/A 2012-11-14
Q3 2010 $4.24M Jul 1, 2010 Sep 30, 2010 10-Q/A 2012-02-10
Q2 2010 $3.96M Apr 1, 2010 Jun 30, 2010 10-Q/A 2012-02-10
* An asterisk sign (*) next to the value indicates that the value is likely invalid.